# US 2018/0022822 A1 · Novel anti-fibroblast activation protein (fap) binding agents and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022822 A1
- Document ID: US20180022822A1
- Status: Published application
- Kind: A1
- Application number: 15/648,246
- Filed: 2017-07-12
- Published: 2018-01-25
- Earliest claimed: 2016-07-13
- Assignees: Mabimmune Diagnostics AG
- Applicants: Mabimmune Diagnostics AG
- Inventors: Chad BROKOPP; Jan Grimm; Benoit Combaluzier; Manuel Tobias Gersbacher
- Web page: https://patentgrep.com/patent/US20180022822A1

## CPC

- C07K 16/40: against enzymes
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/48: of the pancreatic hormones
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 16/30: from tumour cells
- C12Y 304/14005: Dipeptidyl-peptidase IV (3.4.14.5)
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/40: characterized by post-translational modification
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/70: containing domain for protein-protein interaction
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, and chimeric antigen receptors (CARs) directed against the human FAP antigen as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A monoclonal human B cell-derived anti-Fibroblast Activation Protein (FAP) antibody, or a biotechnological or synthetic derivative thereof, wherein at least one of the complementarity determining regions (CDRs) and/or variable heavy chain and/or variable light chain of the antibody are encoded by a cDNA derived from an mRNA obtained from a human memory B cell which produced an anti-FAP antibody.

### Claim 17 (depends on 16)

The antibody of claim 16, which:
(a) is capable of binding to captured or directly coated human FAP with an EC50 of ≦0.1 μM;
(b) is capable of binding a FAP epitope in a peptide of 15 amino acids in length, wherein the epitope comprises the amino acid sequence of any one of SEQ ID NOs: 30-37, 60, and 61;
(c) is capable of binding a FAP epitope in a peptide of 15 amino acids in length, wherein the epitope consists of the amino acid sequence of any one of SEQ ID NOs: 30-37, 60, and 61;
(d) is capable of binding to transmembrane FAP;
(e) comprises a human constant region, and/or an Fc region or a region equivalent to an Fc region; or
(f) comprises a glyco-engineered Fc region and has an increased proportion of non-fucosylated oligosaccharides in the Fc region as compared to a non-glyco-engineered antibody.

### Claim 18 (depends on 16)

The antibody of claim 16, comprising in its variable region or binding domain:
(a) at least one CDR of any one of SEQ ID NOs: 62-130;
(b) a variable heavy chain amino acid sequence of any one of SEQ ID NOs: 2, 4, 8, 12, 16, 20, 24, 41, 45, 49, 53, and 57, and/or a variable light chain amino acid sequence of any one of SEQ ID NOs: 6, 10, 14, 18, 22, 26, 43, 47, 51, 55, and 59;
(c) at least one CDR consisting of an amino acid sequence resulting from a partial alteration of any one of the amino acid sequences of (a); or
(d) a variable heavy chain and/or a variable light chain comprising an amino acid sequence resulting from a partial alteration of the amino acid sequence of (b).

### Claim 19 (depends on 18)

The antibody of claim 18, wherein the partial alteration comprises alterations of less than 50% of the amino acid residues in any one of the amino acid sequences of (a) or of the amino acid sequence of (b).

### Claim 20 (depends on 16)

The antibody of claim 16, which shows a higher avidity of binding to FAP under acidic pH as compared to neutral or physiological pH.

### Claim 21 (depends on 20)

The antibody of claim 20, wherein the acidic pH is 6.4 or 6.8, and the physiological pH is 7.4.

### Claim 22 (depends on 16)

The antibody of claim 16, comprising in its variable region or binding domain:
(a) at least one CDR of any one of SEQ ID NOs: 62-76, 83-88, 101-106, and 113-118;
(b) a variable heavy chain amino acid sequence of any one of SEQ ID NOs: 2, 4, 8, 16, 41, and 49, and/or a variable light chain amino acid sequence of any one of SEQ ID NOs: 6, 10, 18, 43, and 51;
(c) at least one CDR consisting of an amino acid sequence resulting from a partial alteration of any one of the amino acid sequences of (a); or
(d) a variable heavy chain and/or a variable light chain comprising an amino acid sequence resulting from a partial alteration of the amino acid sequence of (b).

### Claim 23 (depends on 22)

The antibody of claim 22, which is capable of binding a FAP epitope in a peptide of 15 amino acids in length, wherein the epitope comprises the amino acid sequence of any one of SEQ ID NOs: 30-33, 35, 60, and 61.

### Claim 24 (depends on 23)

The antibody of claim 23, wherein the epitope consists of the amino acid sequence of any one of SEQ ID NOs: 30-33, 35, 60, and 61.

### Claim 25 (depends on 16)

The antibody of claim 16, wherein the antibody binds to FAP and at least one additional epitope and/or target.

### Claim 26 (depends on 25)

The antibody of claim 25, wherein the antibody is bispecific or multivalent.

### Claim 27 (depends on 26)

The antibody of claim 26, wherein the antibody is a bispecific antibody, a trifunctional antibody, a tetrabody, a bivalent single chain fragment (ScFv), a bispecific T-cell engager (BiTE), a bispecific killer cell engager (BiKE), a dual affinity retargeting molecule (DART), or a DuoBody.

### Claim 28 (depends on 25)

The antibody of claim 25, wherein the antibody further binds to death receptor 5 (DR5) and/or CD3, in addition to FAP.

### Claim 29 (depends on 16)

A chimeric antigen receptor (CAR), wherein an antigen bound by the CAR is FAP, wherein the CAR comprises a first receptor comprising a variable region or a binding domain derived from the anti-FAP antibody of claim 16.

### Claim 30 (depends on 29)

The CAR of claim 29, wherein the CAR or a cell expressing the CAR exhibits a higher avidity of binding to FAP, or a cell expressing FAP on its cell surface, under acid pH as compared to neutral or physiological pH.

### Claim 31 (depends on 30)

The CAR of claim 30, wherein the acidic pH is 6.4 or 6.8, and the physiological pH is 7.4.

### Claim 32 (depends on 29)

The CAR of claim 29, wherein the first receptor or a second receptor comprises at least one further antigen binding domain.

### Claim 33 (depends on 32)

The CAR of claim 32, wherein the further antigen binding domain is specific for a CD3 receptor or a death receptor.

### Claim 34 (depends on 33)

The CAR of claim 33, wherein the death receptor is the death receptor 5 (DR5).

### Claim 35 (depends on 29)

The CAR of claim 29, wherein the CAR comprises an extracellular domain, a transmembrane domain, and an intracellular signaling domain.

### Claim 36 (depends on 35)

The CAR of claim 35, wherein the intracellular signaling domain comprises a 4-1 BB costimulatory domain, a CD28 costimulatory domain, and/or a CD3ζ endodomain.

### Claim 37 (depends on 29)

A host cell genetically modified to express the CAR of claim 29, wherein the host cell optionally expresses and secretes a monoclonal human B cell-derived anti-FAP antibody, or a biotechnological or synthetic derivative thereof, wherein at least one of the CDRs and/or VH chain and/or VL chain of the antibody are encoded by a cDNA derived from an mRNA obtained from a human memory B cell which produced an anti-FAP antibody.

### Claim 38 (depends on 37)

The host cell of claim 37, wherein the host cell is a T cell, a cytotoxic T lymphocyte (CTL), a natural killer cell, a hematopoietic stem cell (HSC), an embryonic stem cell, or a pluripotent stem cell.

### Claim 39 (depends on 38)

The host cell of claim 38, wherein the T cell is a CAR T cell.

### Claim 40 (depends on 37)

The host cell of claim 37, wherein host cell exhibits a higher avidity of binding to FAP, or cell expressing FAP on its cell surface, under acidic pH as compared to neutral or physiological pH.

### Claim 41 (depends on 40)

The host cell of claim 40, wherein the acidic pH is 6.4 or 6.8, and the physiological pH is 7.4.

### Claim 42 (depends on 37)

A pharmaceutical or diagnostic composition comprising:
(a) a monoclonal human B cell-derived anti-FAP antibody, or a biotechnological or synthetic derivative thereof, wherein at least one of the CDRs and/or VH chain and/or VL chain of the antibody are encoded by a cDNA derived from an mRNA obtained from a human memory B cell which produced an anti-FAP antibody;
(b) a CAR, wherein an antigen bound by the CAR is FAP, wherein the CAR comprises a first receptor comprising a variable region or a binding domain derived from the anti-FAP antibody of part (a); or
(c) the host cell of claim 37.

### Claim 43 (depends on 37)

A method of treating a subject having a disease or disorder characterized by abnormal expression of FAP, the method comprising administering to the subject in need thereof a therapeutically effective amount of:
(a) a monoclonal human B cell-derived anti-FAP antibody, or a biotechnological or synthetic derivative thereof, wherein at least one of the CDRs and/or VH chain and/or VL chain of the antibody are encoded by a cDNA derived from an mRNA obtained from a human memory B cell which produced an anti-FAP antibody;
(b) a CAR, wherein an antigen bound by the CAR is FAP, wherein the CAR comprises a first receptor comprising a variable region or a binding domain derived from the anti-FAP antibody of part (a);
(c) the host cell of claim 37; or
(d) a pharmaceutical composition comprising any one of (a)-(c).

### Claim 44 (depends on 43)

The method of claim 43, wherein the disease or disorder characterized by abnormal expression of FAP is cancer.
